Biliary excretion of imatinib mesylate and its metabolite CGP 74588 in humans.

about

Biliary excretion of imatinib and its active metabolite CGP74588 during severe hepatic dysfunction.Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles.

P2860

Q33908105-FAABCDD6-E640-47D4-B71E-0A4AAA2C882D Q43841175-A071F092-46DF-41FB-A8DC-146F71809B19

P2860

Biliary excretion of imatinib mesylate and its metabolite CGP 74588 in humans.

Item

http://www.wikidata.org/entity/Q45087236

description

2004 nî lūn-bûn

@nan

2004年の論文

@ja

2004年学术文章

@wuu

2004年学术文章

@zh

2004年学术文章

@zh-cn

2004年学术文章

@zh-hans

2004年学术文章

@zh-my

2004年学术文章

@zh-sg

2004年學術文章

@yue

2004年學術文章

@zh-hant

name

Biliary excretion of imatinib mesylate and its metabolite CGP 74588 in humans.

@en

Biliary excretion of imatinib mesylate and its metabolite CGP 74588 in humans.

@nl

type

Item

label

Biliary excretion of imatinib mesylate and its metabolite CGP 74588 in humans.

@en

Biliary excretion of imatinib mesylate and its metabolite CGP 74588 in humans.

@nl

prefLabel

Biliary excretion of imatinib mesylate and its metabolite CGP 74588 in humans.

@en

Biliary excretion of imatinib mesylate and its metabolite CGP 74588 in humans.

@nl

P1476

Biliary excretion of imatinib mesylate and its metabolite CGP 74588 in humans.

@en

P2093

Merrill J Egorin

http://www.w3.org/2001/XMLSchema#string

Michael J Hayes

http://www.w3.org/2001/XMLSchema#string

Ramesh K Ramanathan

http://www.w3.org/2001/XMLSchema#string

Sakkaraiappan Ramalingam

http://www.w3.org/2001/XMLSchema#string

Theodore F Lagattuta

http://www.w3.org/2001/XMLSchema#string

P2860

Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

Quantification of the anti-leukemia drug STI571 (Gleevec) and its metabolite (CGP 74588) in monkey plasma using a semi-automated solid phase extraction procedure and liquid chromatography-tandem mass spectrometry.

Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor.

Imatinib mesylate--a new oral targeted therapy.

Liquid chromatographic-mass spectrometric assay for quantitation of imatinib and its main metabolite (CGP 74588) in plasma.

Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study.

Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia.

Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects.

P304

1232-1235

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1592/PHCO.24.13.1232.38095

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2004-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15460185

http://www.w3.org/2001/XMLSchema#string

Biliary excretion of imatinib mesylate and its metabolite CGP 74588 in humans.

about

P2860

P2860

Biliary excretion of imatinib mesylate and its metabolite CGP 74588 in humans.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698